A team investigating how tumors respond to immunotherapy reports that complement component C3 plays a decisive role—but only when it acts locally within the tumor microenvironment. Their findings, reported in Nature Communications, suggest that immune checkpoint blockade (ICB) efficacy can be shaped by where C3 is produced and how it influences myeloid cells that accumulate in and around tumors.
The study centers on a crucial distinction: circulating C3 versus complement C3 generated locally in tissues. While systemic complement activity has long been viewed as an immunomodulatory force, the researchers show that local C3 production is the determinant that tunes the inflammatory landscape relevant to checkpoint therapy. In other words, C3’s location, not merely its presence, governs treatment outcomes.
Mechanistically, local C3 was found to affect recruitment and behavior of myeloid populations that include macrophage- and monocyte-like cells. These cells are increasingly recognized as gatekeepers of tumor immunity, capable of either promoting anti-tumor T cell activity or suppressing it through cytokines, phagocytic programs, and antigen presentation pathways.
Using experimental models of ICB, the authors demonstrate that altering local complement C3 disrupts the immune cell composition inside tumors. Changes in myeloid infiltration correlated with differences in checkpoint response, indicating that complement-driven myeloid remodeling is a key step linking innate signals to adaptive anti-tumor immunity.
The work also supports a view of complement as a “local wiring” system for the tumor niche. By regulating myeloid cell trafficking and functional state, locally produced C3 can steer the tumor microenvironment toward either a permissive or inhibitory condition for T cell–mediated tumor killing during ICB.
Importantly, the results argue against a simplistic model in which systemic complement alone determines success. Instead, the paper highlights that locally available C3 can create microgradients of complement activity that reshape chemokine networks and myeloid recruitment programs at the tumor site.
From a translational perspective, the findings raise the possibility that therapies targeting C3 might need to be designed with spatial selectivity in mind. Broad systemic complement inhibition could carry trade-offs, whereas strategies that modulate tumor-local complement activation may preserve beneficial immune functions elsewhere while improving ICB performance.
Overall, this viral-science-news report reframes C3 as a spatial regulator of myeloid infiltration rather than a generic background immune factor. If confirmed in further studies, the concept of “local complement control” could guide next-generation immunotherapy combinations and patient stratification.
As immunotherapy strategies evolve, attention is shifting from single immune pathways to the architecture of tumor microenvironments. This study adds a compelling new piece: local complement C3 helps decide whether checkpoint blockade will succeed by controlling the innate immune cells that shape the battlefield.
Subject of Research: Immune checkpoint blockade efficacy and the role of complement C3 in shaping myeloid cell infiltration within the tumor microenvironment.
Article Title: Local, but not circulating, complement C3 shapes immune checkpoint blockade efficacy by controlling myeloid cell infiltration.
Article References: Miyai, Y., Shiraki, Y., Ando, R. et al. Local, but not circulating, complement C3 shapes immune checkpoint blockade efficacy by controlling myeloid cell infiltration. Nature Communications (2026). https://doi.org/10.1038/s41467-026-75542-3
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41467-026-75542-3
Keywords: complement C3; immune checkpoint blockade; myeloid infiltration; tumor microenvironment; local complement activity; immune modulation
